NASDAQ:TTOO - T2 Biosystems Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.83
  • Forecasted Upside: 119.38 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.01 (-0.77%)
1 month | 3 months | 12 months
Get New T2 Biosystems Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TTOO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TTOO

Average Price Target: $2.83
▲ +119.38% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for T2 Biosystems in the last 3 months. The average price target is $2.83, with a high forecast of $3.50 and a low forecast of $1.65. The average price target represents a 119.38% upside from the last price of $1.29.


The current consensus among 5 polled investment analysts is to buy stock in T2 Biosystems. This rating has held steady since September 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/14/2021SVB LeerinkReiterated RatingBuy$3.00Medium
3/5/2021Alliance Global PartnersLower Price TargetNeutral$2.40 ➝ $1.65High
1/27/2021JonestradingReiterated RatingBuy$3.50High
1/27/2021Alliance Global PartnersDowngradeBuy ➝ Neutral$2.60 ➝ $2.40High
1/27/2021SVB LeerinkLower Price TargetOutperform$4.00 ➝ $3.00High
1/26/2021Canaccord GenuityReiterated RatingBuy$3.50High
11/5/2020Canaccord GenuityLower Price TargetBuy$4.00 ➝ $3.50Low
11/5/2020Alliance Global PartnersBoost Price TargetBuy$1.65 ➝ $2.60Medium
11/5/2020SVB LeerinkBoost Price TargetOutperform$3.00 ➝ $4.00High
10/7/2020BTIG ResearchInitiated CoverageBuy$2.50Low
8/12/2020SVB LeerinkBoost Price TargetOutperform$2.00 ➝ $3.00High
7/16/2020Canaccord GenuityBoost Price TargetBuy$3.00 ➝ $4.00High
5/6/2020SVB LeerinkReiterated RatingOutperform$5.00 ➝ $2.00High
2/25/2020Canaccord GenuityReiterated RatingBuy$3.00High
1/23/2020Alliance Global PartnersUpgradeNeutral ➝ BuyHigh
11/26/2019Janney Montgomery ScottDowngradeBuy ➝ NeutralHigh
11/21/2019HC WainwrightReiterated RatingHoldMedium
11/13/2019Canaccord GenuityReiterated RatingBuy$3.00High
10/21/2019Canaccord GenuitySet Price TargetBuy$3.50Low
9/12/2019SVB LeerinkSet Price TargetBuy$5.00Low
9/12/2019Janney Montgomery ScottUpgradeNeutral ➝ Buy$6.00High
9/11/2019Canaccord GenuityReiterated RatingBuy$2.50 ➝ $3.50High
9/11/2019Janney Montgomery ScottReiterated RatingFair Value ➝ Neutral$2.00High
8/7/2019HC WainwrightReiterated RatingHoldMedium
8/1/2019Alliance Global PartnersDowngradeBuy ➝ Neutral$5.00 ➝ $0.40High
7/31/2019HC WainwrightDowngradeBuy ➝ NeutralHigh
7/31/2019Cantor FitzgeraldDowngradeOverweight ➝ NeutralHigh
7/31/2019Janney Montgomery ScottDowngradeBuy ➝ NeutralHigh
6/7/2019HC WainwrightSet Price TargetBuy$10.00High
5/31/2019HC WainwrightSet Price TargetBuy$10.00Medium
5/24/2019Cantor FitzgeraldSet Price TargetBuy$10.00Low
5/20/2019HC WainwrightReiterated RatingBuy$11.00High
5/16/2019Alliance Global PartnersInitiated CoverageBuy$5.00High
5/3/2019Cantor FitzgeraldReiterated RatingBuy$10.00High
3/8/2019HC WainwrightReiterated RatingBuy ➝ Buy$14.00 ➝ $11.00High
3/5/2019Cantor FitzgeraldSet Price TargetBuy$11.00High
3/5/2019Canaccord GenuityReiterated RatingBuy$10.00High
11/30/2018The Goldman Sachs GroupSet Price TargetHold$5.00High
11/2/2018HC WainwrightSet Price TargetBuy$14.00High
11/2/2018Cantor FitzgeraldSet Price TargetBuy$11.00High
10/8/2018HC WainwrightReiterated RatingBuy$14.00High
9/26/2018Cantor FitzgeraldSet Price TargetBuy$11.00High
9/20/2018Cantor FitzgeraldInitiated CoverageBuy$11.00Low
8/3/2018HC WainwrightSet Price TargetBuy$14.00High
6/14/2018HC WainwrightReiterated RatingBuy$14.00Medium
6/1/2018SVB LeerinkUpgradeMarket Perform ➝ OutperformHigh
5/30/2018HC WainwrightReiterated RatingBuy$8.50 ➝ $14.00High
5/9/2018HC WainwrightSet Price TargetBuy$9.00High
5/9/2018Janney Montgomery ScottUpgradeNeutral ➝ BuyHigh
3/29/2018HC WainwrightBoost Price TargetBuy ➝ Buy$8.00 ➝ $8.50Low
3/7/2018HC WainwrightSet Price TargetBuy$8.00Low
2/12/2018HC WainwrightSet Price TargetBuy$8.00Low
1/29/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$5.20High
1/25/2018HC WainwrightReiterated RatingBuy$8.00Medium
11/3/2017HC WainwrightReiterated RatingBuy$8.00N/A
10/30/2017Canaccord GenuityReiterated RatingBuy$6.00N/A
10/18/2017HC WainwrightInitiated CoverageBuy ➝ Buy$8.00N/A
5/8/2017BTIG ResearchUpgradeSell ➝ Neutral$4.00High
5/3/2017Cantor FitzgeraldLower Price TargetOverweight$7.00 ➝ $6.00High
3/14/2017Morgan StanleyDowngradeEqual Weight ➝ Underweight$5.00High
3/8/2017Cantor FitzgeraldSet Price TargetBuy$7.00Low
2/14/2017Canaccord GenuitySet Price TargetBuy$9.00N/A
2/14/2017Cantor FitzgeraldSet Price TargetBuy$7.00N/A
2/5/2017WBB SecuritiesReiterated RatingBuy$12.00N/A
1/23/2017Canaccord GenuitySet Price TargetBuy$9.00N/A
11/10/2016SVB LeerinkReiterated RatingMarket Perform$5.00N/A
11/2/2016Cantor FitzgeraldLower Price TargetBuy$10.00 ➝ $9.00N/A
9/22/2016Canaccord GenuityReiterated RatingBuy$9.00N/A
8/2/2016Canaccord GenuityLower Price TargetBuy$10.00 ➝ $9.00N/A
7/20/2016WBB SecuritiesUpgradeBuy ➝ Strong-Buy$11.00 ➝ $12.00N/A
7/10/2016SVB LeerinkReiterated RatingBuyN/A
7/9/2016Cantor FitzgeraldReiterated RatingBuyN/A
7/9/2016Janney Montgomery ScottReiterated RatingHoldN/A
7/8/2016WBB SecuritiesReiterated RatingBuy$11.00N/A
7/8/2016BTIG ResearchDowngradeBuy ➝ Sell$12.00 ➝ $4.00N/A
6/22/2016WBB SecuritiesUpgradeSpeculative Buy ➝ Buy$11.00N/A
6/21/2016Cantor FitzgeraldReiterated RatingBuy$15.00N/A
(Data available from 6/21/2016 forward)
T2 Biosystems logo
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance technology that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida Panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood. In addition, it provides T2Bacteria Panel, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; T2SARS-CoV-2 Panel, a COVID-19 molecular diagnostic test; and T2Resistance Panel for the early and sensitive detection of carbapenemase-resistance markers. Further, it develops T2Cauris Panel, a multi-drug resistant pathogen; and T2Lyme Panel for the detection of various strains of Lyme disease-causing bacteria. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Read More

Today's Range

Now: $1.29
Low: $1.25
High: $1.33

50 Day Range

MA: $1.27
Low: $1.04
High: $1.47

52 Week Range

Now: $1.29
Low: $1.01
High: $3.79


2,862,200 shs

Average Volume

9,120,946 shs

Market Capitalization

$193.64 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of T2 Biosystems?

The following sell-side analysts have issued reports on T2 Biosystems in the last twelve months: Alliance Global Partners, BTIG Research, Canaccord Genuity, Jonestrading, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for TTOO.

What is the current price target for T2 Biosystems?

5 Wall Street analysts have set twelve-month price targets for T2 Biosystems in the last year. Their average twelve-month price target is $2.83, suggesting a possible upside of 119.4%. Canaccord Genuity has the highest price target set, predicting TTOO will reach $3.50 in the next twelve months. Alliance Global Partners has the lowest price target set, forecasting a price of $1.65 for T2 Biosystems in the next year.
View the latest price targets for TTOO.

What is the current consensus analyst rating for T2 Biosystems?

T2 Biosystems currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TTOO will outperform the market and that investors should add to their positions of T2 Biosystems.
View the latest ratings for TTOO.

What other companies compete with T2 Biosystems?

How do I contact T2 Biosystems' investor relations team?

T2 Biosystems' physical mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The medical equipment provider's listed phone number is 781-761-4646 and its investor relations email address is [email protected] The official website for T2 Biosystems is